Edition:
United Kingdom

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

164.65USD
8:59pm GMT
Change (% chg)

$4.21 (+2.62%)
Prev Close
$160.44
Open
$159.77
Day's High
$165.50
Day's Low
$159.59
Volume
368,028
Avg. Vol
271,381
52-wk High
$173.28
52-wk Low
$44.58

Chart for

About

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and... (more)

Overall

Beta: --
Market Cap(Mil.): $2,399.97
Shares Outstanding(Mil.): 37.44
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

Sage shares surge as depression drug succeeds in mid-stage trial

Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.

07 Dec 2017

UPDATE 3-Sage shares surge as depression drug succeeds in mid-stage trial

* Shares surge as much as 85 pct (Adds details on drug's mechanism, analyst comment, updates shares)

07 Dec 2017

Sage's depression drug succeeds in mid-stage study

Dec 7 Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

07 Dec 2017

BRIEF-Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share

* SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE Source text for Eikon: Further company coverage:

15 Nov 2017

BRIEF-Sage Therapeutics announces proposed public offering of common stock

* Sage Therapeutics announces proposed public offering of common stock

13 Nov 2017

Sage soars as postpartum depression drug moves closer to approval

Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.

09 Nov 2017

UPDATE 3-Sage soars as postpartum depression drug moves closer to approval

* Shares zoom about 55 pct to all-time high (Adds details from conference call, analyst comments and background on disease space)

09 Nov 2017

REFILE-Sage Therapeutics postpartum depression drug meets main goal

Nov 9 Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies.

09 Nov 2017

BRIEF-Sage Therapeutics announces Brexanolone achieves primary endpoints

* Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression

09 Nov 2017

BRIEF-Sage Therapeutics announces qtrly loss per share $1.97‍​

* Sage Therapeutics announces third quarter 2017 financial results and provides pipeline update

02 Nov 2017

Earnings vs. Estimates